Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
Iris
I
Lee
Serban
S
Constantinescu
Avrum
A
Gillespie
Abhishek
A
Swami
Mark
M
Birkenbach
Stephen
S
Leech
Patricio
P
Silva
Andreas
A
Karachristos
John A
JA
Daller
Nicole M
NM
Sifontis
D001402:B-Lymphocytes / Q000276:immunology; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology
D001897:Boronic Acids; D016756:Immunoglobulins, Intravenous; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003404:Creatinine